AZD5213 + pregabalin + Placebo + pregabalin capsules
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Diabetic Neuropathy, Painful; Diabetic Neuropathies
Conditions
Diabetic Neuropathy, Painful; Diabetic Neuropathies
Trial Timeline
Nov 1, 2013 → May 1, 2015
NCT ID
NCT01928381About AZD5213 + pregabalin + Placebo + pregabalin capsules
AZD5213 + pregabalin + Placebo + pregabalin capsules is a phase 2 stage product being developed by AstraZeneca for Diabetic Neuropathy, Painful; Diabetic Neuropathies. The current trial status is completed. This product is registered under clinical trial identifier NCT01928381. Target conditions include Diabetic Neuropathy, Painful; Diabetic Neuropathies.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01928381 | Phase 2 | Completed |
Competing Products
20 competing products in Diabetic Neuropathy, Painful; Diabetic Neuropathies